Croda International (CRDA)

Sector:

Industrial Chemicals

Index:

FTSE 100

4,703.00p
   
  • Change Today:
      54.00p
  • 52 Week High: 6,980.00
  • 52 Week Low: 4,076.00
  • Currency: UK Pounds
  • Shares Issued: 142.54m
  • Volume: 327,267
  • Market Cap: £6,704m
  • RiskGrade: 108

Croda warns on margins as profits slump on weak demand

By Frank Prenesti

Date: Tuesday 27 Feb 2024

LONDON (ShareCast) - (Sharecast News) - British speciality chemicals maker Croda International on Tuesday warned of lower operating margins this year after posting a slump in 2023 profits due to customers destocking and a weak macroeconomic environment.
Pre-tax profit for the year to December 31 fell 69.7% to £236.3m. The company, which supplies the consumer and life sciences industries, said it expected group adjusted operating margin to be two to three percentage points lower and adjusted profit before tax to be between £260m and £300m in full year 2024.

The FTSE 100-listed company benefited greatly from the Covid-19 pandemic, including making the lipids for the Pfizer-BioNTech vaccine. However, as supply chains began to constrict after lockdowns eased customers built up stock to cope with the post-crisis surge in orders.

This led Croda to cut full-year forecasts last October, with adjusted pre-tax profit expected to come in at £300m - £320m, down from previous guidance of £370m - £400m. The 2023 figure came in at the low end at £308m but beat the £300m consensus of analyst estimates compiled by the company.

"Given the ongoing uncertainty in our end markets, the recovery trajectory for each of our business units remains difficult to predict and the range of possible outcomes in 2024 is therefore wider than usual at this stage of the year," Croda said.

"Overall, however, the Group expects to deliver mid to high single digit percentage sales growth in 2024, excluding the $60m of Covid-19 lipid sales in 2023, with higher sales volumes more than offsetting lower price/mix."

It added that its consumer care division had started the year well and the board was "cautiously optimistic" about the improving demand trend we experienced January.

"Within Life Sciences, we expect the non-Covid pharma business to grow but that destocking will continue in crop protection. Demand in industrial specialties is expected to remain weak."

Reporting by Frank Prenesti for Sharecast.com

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

CRDA Market Data

Currency UK Pounds
Share Price 4,703.00p
Change Today 54.00p
% Change 1.16 %
52 Week High 6,980.00
52 Week Low 4,076.00
Volume 327,267
Shares Issued 142.54m
Market Cap £6,704m
RiskGrade 108

CRDA Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
82.44% below the market average82.44% below the market average82.44% below the market average82.44% below the market average82.44% below the market average
88.24% below the sector average88.24% below the sector average88.24% below the sector average88.24% below the sector average88.24% below the sector average
Price Trend
30.08% below the market average30.08% below the market average30.08% below the market average30.08% below the market average30.08% below the market average
55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average55.56% above the sector average
Income
83.23% below the market average83.23% below the market average83.23% below the market average83.23% below the market average83.23% below the market average
Sector averageSector averageSector averageSector averageSector average
Growth
87.09% below the market average87.09% below the market average87.09% below the market average87.09% below the market average87.09% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

What The Brokers Say

Strong Buy 5
Buy 1
Neutral 9
Sell 0
Strong Sell 1
Total 16
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

CRDA Dividends

  Latest Previous
  Final Interim
Ex-Div 18-Apr-24 31-Aug-23
Paid 29-May-24 03-Oct-23
Amount 62.00p 47.00p

Trades for 26-Apr-2024

Time Volume / Share Price
16:39 5,000 @ 4,703.00p
16:39 8,398 @ 4,703.00p
16:35 155,539 @ 4,703.00p
16:35 163 @ 4,703.00p
16:35 941 @ 4,703.00p

CRDA Key Personnel

Finance Director Louisa Burdett

Top of Page